APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-angiogenic Ophthalmic Agent

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-angiogenic Ophthalmic Agent Market Analysis and Forecast 2026-2032

22 December 2025203 pages

Choose your research edition.

Industry ResearchAnti-angiogenic Ophthalmic Agent Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-angiogenic Ophthalmic Agent Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-angiogenic Ophthalmic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-angiogenic Ophthalmic Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-angiogenic Ophthalmic Agent Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Anti-angiogenic Ophthalmic Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-angiogenic Ophthalmic Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-angiogenic Ophthalmic Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-angiogenic Ophthalmic Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-angiogenic Ophthalmic Agent is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Anti-angiogenic Ophthalmic Agent include Sun Pharma, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG, The Geuder Group, MORCHER GmbH and Shanghai Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-angiogenic Ophthalmic Agent, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-angiogenic Ophthalmic Agent, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-angiogenic Ophthalmic Agent, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-angiogenic Ophthalmic Agent sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-angiogenic Ophthalmic Agent market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anti-angiogenic Ophthalmic Agent sales, projected growth trends, production technology, application and end-user industry.

Anti-angiogenic Ophthalmic Agent Segment by Company

Sun Pharma

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Pfizer

Daiichi Sankyo

Bayer AG

The Geuder Group, MORCHER GmbH

Shanghai Pharmaceuticals

Santen Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd

Novamedika

Medicom Health care

Implant ophthalmic products GmbH

Genentech, Inc.

Eyetech Inc.

ERC Labs

Becton, Dickinson and Company

Allergan plc

Anti-angiogenic Ophthalmic Agent Segment by Type

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Macular Edema

Macular Degeneration

Anti-angiogenic Ophthalmic Agent Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Anti-angiogenic Ophthalmic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-angiogenic Ophthalmic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-angiogenic Ophthalmic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-angiogenic Ophthalmic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anti-angiogenic Ophthalmic Agent in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anti-angiogenic Ophthalmic Agent manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-angiogenic Ophthalmic Agent sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Diabetic Retinopathy Major Manufacturers Table 3. Myopic Choroidal Neovascularization Major Manufacturers Table 4. Macular Edema Major Manufacturers Table 5. Macular Degeneration Major Manufacturers Table 6. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacies Major Manufacturers Table 8. Online Pharmacies Major Manufacturers Table 9. Retail Pharmacies Major Manufacturers Table 10. Anti-angiogenic Ophthalmic Agent Industry Trends Table 11. Anti-angiogenic Ophthalmic Agent Industry Drivers Table 12. Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges Table 13. Anti-angiogenic Ophthalmic Agent Industry Restraints Table 14. Global Anti-angiogenic Ophthalmic Agent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2021-2026) Table 18. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2027-2032) Table 19. Global Anti-angiogenic Ophthalmic Agent Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026) & (k units) Table 21. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2027-2032) & (k units) Table 22. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2021-2026) Table 23. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2027-2032) Table 24. Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Manufacturers (2021-2026) Table 28. Global Anti-angiogenic Ophthalmic Agent Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global Anti-angiogenic Ophthalmic Agent Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Anti-angiogenic Ophthalmic Agent Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Anti-angiogenic Ophthalmic Agent Manufacturers, Product Type & Application Table 32. Global Anti-angiogenic Ophthalmic Agent Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Anti-angiogenic Ophthalmic Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Anti-angiogenic Ophthalmic Agent Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2026) Table 39. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2027-2032) Table 40. Global Anti-angiogenic Ophthalmic Agent Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 42. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 43. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2026) Table 44. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2027-2032) Table 45. Global Anti-angiogenic Ophthalmic Agent Price by Type (2021-2026) & (US$/unit) Table 46. Global Anti-angiogenic Ophthalmic Agent Price by Type (2027-2032) & (US$/unit) Table 47. Global Anti-angiogenic Ophthalmic Agent Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2026) Table 51. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2027-2032) Table 52. Global Anti-angiogenic Ophthalmic Agent Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 54. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 55. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2026) Table 56. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2027-2032) Table 57. Global Anti-angiogenic Ophthalmic Agent Price by Application (2021-2026) & (US$/unit) Table 58. Global Anti-angiogenic Ophthalmic Agent Price by Application (2027-2032) & (US$/unit) Table 59. Sun Pharma Company Information Table 60. Sun Pharma Business Overview Table 61. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio Table 63. Sun Pharma Recent Development Table 64. Johnson & Johnson Company Information Table 65. Johnson & Johnson Business Overview Table 66. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio Table 68. Johnson & Johnson Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 73. Novartis AG Recent Development Table 74. Gilead Sciences, Inc. Company Information Table 75. Gilead Sciences, Inc. Business Overview Table 76. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 78. Gilead Sciences, Inc. Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio Table 83. Pfizer Recent Development Table 84. Daiichi Sankyo Company Information Table 85. Daiichi Sankyo Business Overview Table 86. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio Table 88. Daiichi Sankyo Recent Development Table 89. Bayer AG Company Information Table 90. Bayer AG Business Overview Table 91. Bayer AG Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 93. Bayer AG Recent Development Table 94. The Geuder Group, MORCHER GmbH Company Information Table 95. The Geuder Group, MORCHER GmbH Business Overview Table 96. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 98. The Geuder Group, MORCHER GmbH Recent Development Table 99. Shanghai Pharmaceuticals Company Information Table 100. Shanghai Pharmaceuticals Business Overview Table 101. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio Table 103. Shanghai Pharmaceuticals Recent Development Table 104. Santen Pharmaceutical Co., Ltd. Company Information Table 105. Santen Pharmaceutical Co., Ltd. Business Overview Table 106. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 108. Santen Pharmaceutical Co., Ltd. Recent Development Table 109. Regeneron Pharmaceuticals, Inc. Company Information Table 110. Regeneron Pharmaceuticals, Inc. Business Overview Table 111. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 113. Regeneron Pharmaceuticals, Inc. Recent Development Table 114. Otsuka Pharmaceutical Co. Ltd Company Information Table 115. Otsuka Pharmaceutical Co. Ltd Business Overview Table 116. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio Table 118. Otsuka Pharmaceutical Co. Ltd Recent Development Table 119. Novamedika Company Information Table 120. Novamedika Business Overview Table 121. Novamedika Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio Table 123. Novamedika Recent Development Table 124. Medicom Health care Company Information Table 125. Medicom Health care Business Overview Table 126. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio Table 128. Medicom Health care Recent Development Table 129. Implant ophthalmic products GmbH Company Information Table 130. Implant ophthalmic products GmbH Business Overview Table 131. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 133. Implant ophthalmic products GmbH Recent Development Table 134. Genentech, Inc. Company Information Table 135. Genentech, Inc. Business Overview Table 136. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 138. Genentech, Inc. Recent Development Table 139. Eyetech Inc. Company Information Table 140. Eyetech Inc. Business Overview Table 141. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 143. Eyetech Inc. Recent Development Table 144. ERC Labs Company Information Table 145. ERC Labs Business Overview Table 146. ERC Labs Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio Table 148. ERC Labs Recent Development Table 149. Becton, Dickinson and Company Company Information Table 150. Becton, Dickinson and Company Business Overview Table 151. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio Table 153. Becton, Dickinson and Company Recent Development Table 154. Allergan plc Company Information Table 155. Allergan plc Business Overview Table 156. Allergan plc Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio Table 158. Allergan plc Recent Development Table 159. North America Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (US$ Million) Table 160. North America Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (US$ Million) Table 161. North America Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 162. North America Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 163. North America Anti-angiogenic Ophthalmic Agent Sales Price by Type (2021-2026) & (US$/unit) Table 164. North America Anti-angiogenic Ophthalmic Agent Sales Price by Type (2027-2032) & (US$/unit) Table 165. North America Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (US$ Million) Table 166. North America Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (US$ Million) Table 167. North America Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 168. North America Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 169. North America Anti-angiogenic Ophthalmic Agent Sales Price by Application (2021-2026) & (US$/unit) Table 170. North America Anti-angiogenic Ophthalmic Agent Sales Price by Application (2027-2032) & (US$/unit) Table 171. North America Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. North America Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 173. North America Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 174. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 175. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 176. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 177. North America Anti-angiogenic Ophthalmic Agent Sales Price by Country (2021-2026) & (US$/unit) Table 178. North America Anti-angiogenic Ophthalmic Agent Sales Price by Country (2027-2032) & (US$/unit) Table 179. United States Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 180. Canada Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 181. Mexico Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 182. Europe Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (US$ Million) Table 183. Europe Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (US$ Million) Table 184. Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 185. Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 186. Europe Anti-angiogenic Ophthalmic Agent Sales Price by Type (2021-2026) & (US$/unit) Table 187. Europe Anti-angiogenic Ophthalmic Agent Sales Price by Type (2027-2032) & (US$/unit) Table 188. Europe Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (US$ Million) Table 189. Europe Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (US$ Million) Table 190. Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 191. Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 192. Europe Anti-angiogenic Ophthalmic Agent Sales Price by Application (2021-2026) & (US$/unit) Table 193. Europe Anti-angiogenic Ophthalmic Agent Sales Price by Application (2027-2032) & (US$/unit) Table 194. Europe Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. Europe Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. Europe Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 198. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 199. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 200. Europe Anti-angiogenic Ophthalmic Agent Sales Price by Country (2021-2026) & (US$/unit) Table 201. Europe Anti-angiogenic Ophthalmic Agent Sales Price by Country (2027-2032) & (US$/unit) Table 202. Germany Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 203. France Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 204. U.K. Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 205. Italy Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 206. Russia Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 207. Spain Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 208. Netherlands Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 209. Switzerland Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 210. Sweden Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 211. Poland Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 212. China Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (US$ Million) Table 213. China Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (US$ Million) Table 214. China Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 215. China Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 216. China Anti-angiogenic Ophthalmic Agent Sales Price by Type (2021-2026) & (US$/unit) Table 217. China Anti-angiogenic Ophthalmic Agent Sales Price by Type (2027-2032) & (US$/unit) Table 218. China Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (US$ Million) Table 219. China Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (US$ Million) Table 220. China Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 221. China Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 222. China Anti-angiogenic Ophthalmic Agent Sales Price by Application (2021-2026) & (US$/unit) Table 223. China Anti-angiogenic Ophthalmic Agent Sales Price by Application (2027-2032) & (US$/unit) Table 224. Asia Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (US$ Million) Table 225. Asia Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (US$ Million) Table 226. Asia Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 227. Asia Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 228. Asia Anti-angiogenic Ophthalmic Agent Sales Price by Type (2021-2026) & (US$/unit) Table 229. Asia Anti-angiogenic Ophthalmic Agent Sales Price by Type (2027-2032) & (US$/unit) Table 230. Asia Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (US$ Million) Table 231. Asia Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (US$ Million) Table 232. Asia Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 233. Asia Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 234. Asia Anti-angiogenic Ophthalmic Agent Sales Price by Application (2021-2026) & (US$/unit) Table 235. Asia Anti-angiogenic Ophthalmic Agent Sales Price by Application (2027-2032) & (US$/unit) Table 236. Asia Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 237. Asia Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 238. Asia Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 239. Asia Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 240. Asia Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 241. Asia Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 242. Asia Anti-angiogenic Ophthalmic Agent Sales Price by Country (2021-2026) & (US$/unit) Table 243. Asia Anti-angiogenic Ophthalmic Agent Sales Price by Country (2027-2032) & (US$/unit) Table 244. Japan Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 245. South Korea Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 246. India Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 247. Australia Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 248. Taiwan Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 249. Southeast Asia Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 250. SAMEA Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (US$ Million) Table 251. SAMEA Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (US$ Million) Table 252. SAMEA Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 253. SAMEA Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 254. SAMEA Anti-angiogenic Ophthalmic Agent Sales Price by Type (2021-2026) & (US$/unit) Table 255. SAMEA Anti-angiogenic Ophthalmic Agent Sales Price by Type (2027-2032) & (US$/unit) Table 256. SAMEA Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (US$ Million) Table 257. SAMEA Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (US$ Million) Table 258. SAMEA Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 259. SAMEA Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 260. SAMEA Anti-angiogenic Ophthalmic Agent Sales Price by Application (2021-2026) & (US$/unit) Table 261. SAMEA Anti-angiogenic Ophthalmic Agent Sales Price by Application (2027-2032) & (US$/unit) Table 262. SAMEA Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 263. SAMEA Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 264. SAMEA Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 265. SAMEA Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 266. SAMEA Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 267. SAMEA Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 268. SAMEA Anti-angiogenic Ophthalmic Agent Sales Price by Country (2021-2026) & (US$/unit) Table 269. SAMEA Anti-angiogenic Ophthalmic Agent Sales Price by Country (2027-2032) & (US$/unit) Table 270. Brazil Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 271. Argentina Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 272. Chile Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 273. Colombia Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 274. Peru Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 275. Saudi Arabia Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 276. Israel Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 277. UAE Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 278. Turkey Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 279. Iran Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 280. Egypt Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Table 281. Key Raw Materials Table 282. Raw Materials Key Suppliers Table 283. Anti-angiogenic Ophthalmic Agent Distributors List Table 284. Anti-angiogenic Ophthalmic Agent Customers List Table 285. Research Programs/Design for This Report Table 286. Authors List of This Report Table 287. Secondary Sources Table 288. Primary Sources List of Figures Figure 1. Anti-angiogenic Ophthalmic Agent Image Figure 2. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-angiogenic Ophthalmic Agent Market Size Share 2021 VS 2025 VS 2032 Figure 4. Diabetic Retinopathy Image Figure 5. Myopic Choroidal Neovascularization Image Figure 6. Macular Edema Image Figure 7. Macular Degeneration Image Figure 8. Global Anti-angiogenic Ophthalmic Agent Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Anti-angiogenic Ophthalmic Agent Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacies Image Figure 11. Online Pharmacies Image Figure 12. Retail Pharmacies Image Figure 13. Global Anti-angiogenic Ophthalmic Agent Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Anti-angiogenic Ophthalmic Agent Revenue (2021-2032) & (US$ Million) Figure 15. Global Anti-angiogenic Ophthalmic Agent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2021-2032) Figure 18. Global Anti-angiogenic Ophthalmic Agent Sales (2021-2032) & (k units) Figure 19. Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Anti-angiogenic Ophthalmic Agent Sales YoY (2021-2032) & (k units) Figure 22. Europe Anti-angiogenic Ophthalmic Agent Sales YoY (2021-2032) & (k units) Figure 23. China Anti-angiogenic Ophthalmic Agent Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) Anti-angiogenic Ophthalmic Agent Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales YoY (2021-2032) & (k units) Figure 26. Global Anti-angiogenic Ophthalmic Agent Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Anti-angiogenic Ophthalmic Agent Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2032) Figure 32. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2032) Figure 35. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2032) Figure 38. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2032) Figure 41. North America Anti-angiogenic Ophthalmic Agent Revenue Share by Type (2021-2032) Figure 42. North America Anti-angiogenic Ophthalmic Agent Sales Share by Type (2021-2032) Figure 43. North America Anti-angiogenic Ophthalmic Agent Revenue Share by Application (2021-2032) Figure 44. North America Anti-angiogenic Ophthalmic Agent Sales Share by Application (2021-2032) Figure 45. North America Anti-angiogenic Ophthalmic Agent Revenue Share by Country (2021-2032) Figure 46. North America Anti-angiogenic Ophthalmic Agent Sales Share by Country (2021-2032) Figure 47. Europe Anti-angiogenic Ophthalmic Agent Revenue Share by Type (2021-2032) Figure 48. Europe Anti-angiogenic Ophthalmic Agent Sales Share by Type (2021-2032) Figure 49. Europe Anti-angiogenic Ophthalmic Agent Revenue Share by Application (2021-2032) Figure 50. Europe Anti-angiogenic Ophthalmic Agent Sales Share by Application (2021-2032) Figure 51. Europe Anti-angiogenic Ophthalmic Agent Revenue Share by Country (2021-2032) Figure 52. Europe Anti-angiogenic Ophthalmic Agent Sales Share by Country (2021-2032) Figure 53. China Anti-angiogenic Ophthalmic Agent Revenue Share by Type (2021-2032) Figure 54. China Anti-angiogenic Ophthalmic Agent Sales Share by Type (2021-2032) Figure 55. China Anti-angiogenic Ophthalmic Agent Revenue Share by Application (2021-2032) Figure 56. China Anti-angiogenic Ophthalmic Agent Sales Share by Application (2021-2032) Figure 57. Asia Anti-angiogenic Ophthalmic Agent Revenue Share by Type (2021-2032) Figure 58. Asia Anti-angiogenic Ophthalmic Agent Sales Share by Type (2021-2032) Figure 59. Asia Anti-angiogenic Ophthalmic Agent Revenue Share by Application (2021-2032) Figure 60. Asia Anti-angiogenic Ophthalmic Agent Sales Share by Application (2021-2032) Figure 61. Asia Anti-angiogenic Ophthalmic Agent Revenue Share by Country (2021-2032) Figure 62. Asia Anti-angiogenic Ophthalmic Agent Sales Share by Country (2021-2032) Figure 63. SAMEA Anti-angiogenic Ophthalmic Agent Revenue Share by Type (2021-2032) Figure 64. SAMEA Anti-angiogenic Ophthalmic Agent Sales Share by Type (2021-2032) Figure 65. SAMEA Anti-angiogenic Ophthalmic Agent Revenue Share by Application (2021-2032) Figure 66. SAMEA Anti-angiogenic Ophthalmic Agent Sales Share by Application (2021-2032) Figure 67. SAMEA Anti-angiogenic Ophthalmic Agent Revenue Share by Country (2021-2032) Figure 68. SAMEA Anti-angiogenic Ophthalmic Agent Sales Share by Country (2021-2032) Figure 69. Anti-angiogenic Ophthalmic Agent Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Anti-angi

Scope & coverage.

Types
  • Diabetic Retinopathy
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Macular Degeneration
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharma
  • Johnson & Johnson
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer
  • Daiichi Sankyo
  • Bayer AG
  • The Geuder Group, MORCHER GmbH
  • Shanghai Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd
  • Novamedika
  • Medicom Health care
  • Implant ophthalmic products GmbH
  • Genentech, Inc.
  • Eyetech Inc.
  • ERC Labs
  • Becton, Dickinson and Company
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-angiogenic Ophthalmic Agent Market by Type
  3. 1.2.1 Global Anti-angiogenic Ophthalmic Agent Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Diabetic Retinopathy
  5. 1.2.3 Myopic Choroidal Neovascularization
  6. 1.2.4 Macular Edema
  7. 1.2.5 Macular Degeneration
  8. 1.3 Anti-angiogenic Ophthalmic Agent Market by Application
  9. 1.3.1 Global Anti-angiogenic Ophthalmic Agent Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacies
  11. 1.3.3 Online Pharmacies
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Anti-angiogenic Ophthalmic Agent Market Dynamics
  1. 2.1 Anti-angiogenic Ophthalmic Agent Industry Trends
  2. 2.2 Anti-angiogenic Ophthalmic Agent Industry Drivers
  3. 2.3 Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges
  4. 2.4 Anti-angiogenic Ophthalmic Agent Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anti-angiogenic Ophthalmic Agent Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Region
  3. 3.2.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2021-2026)
  5. 3.2.3 Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2027-2032)
  6. 3.2.4 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anti-angiogenic Ophthalmic Agent Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anti-angiogenic Ophthalmic Agent Sales by Region
  9. 3.4.1 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026)
  11. 3.4.3 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2027-2032)
  12. 3.4.4 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers
  2. 4.1.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anti-angiogenic Ophthalmic Agent Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers
  6. 4.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anti-angiogenic Ophthalmic Agent Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anti-angiogenic Ophthalmic Agent Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anti-angiogenic Ophthalmic Agent Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anti-angiogenic Ophthalmic Agent Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anti-angiogenic Ophthalmic Agent Manufacturers, Product Type & Application
  13. 4.7 Global Anti-angiogenic Ophthalmic Agent Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anti-angiogenic Ophthalmic Agent Market CR5 and HHI
  16. 4.8.2 2025 Anti-angiogenic Ophthalmic Agent Tier 1, Tier 2, and Tier 3
5 Anti-angiogenic Ophthalmic Agent Market by Type
  1. 5.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Type
  2. 5.1.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anti-angiogenic Ophthalmic Agent Sales by Type
  6. 5.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anti-angiogenic Ophthalmic Agent Price by Type
6 Anti-angiogenic Ophthalmic Agent Market by Application
  1. 6.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Application
  2. 6.1.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anti-angiogenic Ophthalmic Agent Sales by Application
  6. 6.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anti-angiogenic Ophthalmic Agent Price by Application
7 Company Profiles
  1. 7.1 Sun Pharma
  2. 7.1.1 Sun Pharma Company Information
  3. 7.1.2 Sun Pharma Business Overview
  4. 7.1.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio
  6. 7.1.5 Sun Pharma Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis AG
  14. 7.3.1 Novartis AG Company Information
  15. 7.3.2 Novartis AG Business Overview
  16. 7.3.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  18. 7.3.5 Novartis AG Recent Developments
  19. 7.4 Gilead Sciences, Inc.
  20. 7.4.1 Gilead Sciences, Inc. Company Information
  21. 7.4.2 Gilead Sciences, Inc. Business Overview
  22. 7.4.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  24. 7.4.5 Gilead Sciences, Inc. Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Daiichi Sankyo
  32. 7.6.1 Daiichi Sankyo Company Information
  33. 7.6.2 Daiichi Sankyo Business Overview
  34. 7.6.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio
  36. 7.6.5 Daiichi Sankyo Recent Developments
  37. 7.7 Bayer AG
  38. 7.7.1 Bayer AG Company Information
  39. 7.7.2 Bayer AG Business Overview
  40. 7.7.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  42. 7.7.5 Bayer AG Recent Developments
  43. 7.8 The Geuder Group, MORCHER GmbH
  44. 7.8.1 The Geuder Group, MORCHER GmbH Company Information
  45. 7.8.2 The Geuder Group, MORCHER GmbH Business Overview
  46. 7.8.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  48. 7.8.5 The Geuder Group, MORCHER GmbH Recent Developments
  49. 7.9 Shanghai Pharmaceuticals
  50. 7.9.1 Shanghai Pharmaceuticals Company Information
  51. 7.9.2 Shanghai Pharmaceuticals Business Overview
  52. 7.9.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio
  54. 7.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 7.10 Santen Pharmaceutical Co., Ltd.
  56. 7.10.1 Santen Pharmaceutical Co., Ltd. Company Information
  57. 7.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
  58. 7.10.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio
  60. 7.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
  61. 7.11 Regeneron Pharmaceuticals, Inc.
  62. 7.11.1 Regeneron Pharmaceuticals, Inc. Company Information
  63. 7.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
  64. 7.11.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  66. 7.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
  67. 7.12 Otsuka Pharmaceutical Co. Ltd
  68. 7.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
  69. 7.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
  70. 7.12.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio
  72. 7.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
  73. 7.13 Novamedika
  74. 7.13.1 Novamedika Company Information
  75. 7.13.2 Novamedika Business Overview
  76. 7.13.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio
  78. 7.13.5 Novamedika Recent Developments
  79. 7.14 Medicom Health care
  80. 7.14.1 Medicom Health care Company Information
  81. 7.14.2 Medicom Health care Business Overview
  82. 7.14.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio
  84. 7.14.5 Medicom Health care Recent Developments
  85. 7.15 Implant ophthalmic products GmbH
  86. 7.15.1 Implant ophthalmic products GmbH Company Information
  87. 7.15.2 Implant ophthalmic products GmbH Business Overview
  88. 7.15.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  90. 7.15.5 Implant ophthalmic products GmbH Recent Developments
  91. 7.16 Genentech, Inc.
  92. 7.16.1 Genentech, Inc. Company Information
  93. 7.16.2 Genentech, Inc. Business Overview
  94. 7.16.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  96. 7.16.5 Genentech, Inc. Recent Developments
  97. 7.17 Eyetech Inc.
  98. 7.17.1 Eyetech Inc. Company Information
  99. 7.17.2 Eyetech Inc. Business Overview
  100. 7.17.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  102. 7.17.5 Eyetech Inc. Recent Developments
  103. 7.18 ERC Labs
  104. 7.18.1 ERC Labs Company Information
  105. 7.18.2 ERC Labs Business Overview
  106. 7.18.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio
  108. 7.18.5 ERC Labs Recent Developments
  109. 7.19 Becton, Dickinson and Company
  110. 7.19.1 Becton, Dickinson and Company Company Information
  111. 7.19.2 Becton, Dickinson and Company Business Overview
  112. 7.19.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio
  114. 7.19.5 Becton, Dickinson and Company Recent Developments
  115. 7.20 Allergan plc
  116. 7.20.1 Allergan plc Company Information
  117. 7.20.2 Allergan plc Business Overview
  118. 7.20.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio
  120. 7.20.5 Allergan plc Recent Developments
8 North America
  1. 8.1 North America Anti-angiogenic Ophthalmic Agent Market Size by Type
  2. 8.1.1 North America Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032)
  3. 8.1.2 North America Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032)
  4. 8.1.3 North America Anti-angiogenic Ophthalmic Agent Price by Type (2021-2032)
  5. 8.2 North America Anti-angiogenic Ophthalmic Agent Market Size by Application
  6. 8.2.1 North America Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032)
  7. 8.2.2 North America Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032)
  8. 8.2.3 North America Anti-angiogenic Ophthalmic Agent Price by Application (2021-2032)
  9. 8.3 North America Anti-angiogenic Ophthalmic Agent Market Size by Country
  10. 8.3.1 North America Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anti-angiogenic Ophthalmic Agent Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anti-angiogenic Ophthalmic Agent Market Size by Type
  2. 9.1.1 Europe Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032)
  4. 9.1.3 Europe Anti-angiogenic Ophthalmic Agent Price by Type (2021-2032)
  5. 9.2 Europe Anti-angiogenic Ophthalmic Agent Market Size by Application
  6. 9.2.1 Europe Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032)
  8. 9.2.3 Europe Anti-angiogenic Ophthalmic Agent Price by Application (2021-2032)
  9. 9.3 Europe Anti-angiogenic Ophthalmic Agent Market Size by Country
  10. 9.3.1 Europe Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anti-angiogenic Ophthalmic Agent Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anti-angiogenic Ophthalmic Agent Market Size by Type
  2. 10.1.1 China Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032)
  3. 10.1.2 China Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032)
  4. 10.1.3 China Anti-angiogenic Ophthalmic Agent Price by Type (2021-2032)
  5. 10.2 China Anti-angiogenic Ophthalmic Agent Market Size by Application
  6. 10.2.1 China Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032)
  7. 10.2.2 China Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032)
  8. 10.2.3 China Anti-angiogenic Ophthalmic Agent Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-angiogenic Ophthalmic Agent Market Size by Type
  2. 11.1.1 Asia Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032)
  4. 11.1.3 Asia Anti-angiogenic Ophthalmic Agent Price by Type (2021-2032)
  5. 11.2 Asia Anti-angiogenic Ophthalmic Agent Market Size by Application
  6. 11.2.1 Asia Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032)
  8. 11.2.3 Asia Anti-angiogenic Ophthalmic Agent Price by Application (2021-2032)
  9. 11.3 Asia Anti-angiogenic Ophthalmic Agent Market Size by Country
  10. 11.3.1 Asia Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anti-angiogenic Ophthalmic Agent Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-angiogenic Ophthalmic Agent Market Size by Type
  2. 12.1.1 SAMEA Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anti-angiogenic Ophthalmic Agent Price by Type (2021-2032)
  5. 12.2 SAMEA Anti-angiogenic Ophthalmic Agent Market Size by Application
  6. 12.2.1 SAMEA Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anti-angiogenic Ophthalmic Agent Price by Application (2021-2032)
  9. 12.3 SAMEA Anti-angiogenic Ophthalmic Agent Market Size by Country
  10. 12.3.1 SAMEA Anti-angiogenic Ophthalmic Agent Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anti-angiogenic Ophthalmic Agent Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anti-angiogenic Ophthalmic Agent Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anti-angiogenic Ophthalmic Agent Value Chain Analysis
  2. 13.1.1 Anti-angiogenic Ophthalmic Agent Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anti-angiogenic Ophthalmic Agent Production Mode & Process
  6. 13.2 Anti-angiogenic Ophthalmic Agent Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anti-angiogenic Ophthalmic Agent Distributors
  9. 13.2.3 Anti-angiogenic Ophthalmic Agent Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst